TENX
TENAX THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.86
−1.06%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -62.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -4.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -16.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026